PMID- 26022285
OWN - NLM
STAT- MEDLINE
DCOM- 20151201
LR  - 20161125
IS  - 1769-6917 (Electronic)
IS  - 0007-4551 (Linking)
VI  - 102
IP  - 9
DP  - 2015 Sep
TI  - [Efficacy, safety and cost of eribulin in patients with metastatic breast 
      cancer].
PG  - 737-48
LID - S0007-4551(15)00161-7 [pii]
LID - 10.1016/j.bulcan.2015.03.021 [doi]
AB  - Eribulin gained its approval in March 2011 for the treatment of patients with 
      locally advanced or metastatic breast cancer (MBC) whose disease has progressed 
      despite anthracycline and taxane-containing regimens. This study retrospectively 
      assessed the efficacy, safety and cost of this treatment for all patients with 
      MBC treated by eribulin in Franche-Comte. Ninety-four patients received eribulin 
      between July 2006 and October 2013. The median age was 62 years (35-83). Median 
      overall survival was 10.3 months [95% CI: 7.6 to 17.9]. Median 
      progression-free-survival was 3.8 months [95% CI: 2.9 to 5.0]. Clinical benefit 
      was obtained in 55% evaluable patients [95% CI: 43.1 to 66.9] by RECIST criteria. 
      Most common grade 3-4 adverse events (AEs) were neutropenia (38%), asthenia (10%) 
      and peripheral neuropathy (7%). Median cost of the treatment was 9767 euro per 
      patient (6344-17,517). This analysis found similar results to the EMBRACE study 
      despite less selected population. A medico-economic evaluation cost-utility type 
      would assess the effectiveness of this strategy compared to standard treatments.
CI  - Copyright (c) 2015 Societe Francaise du Cancer. Published by Elsevier Masson SAS. 
      All rights reserved.
FAU - Paillard, Marie-Justine
AU  - Paillard MJ
AD  - CHU de Besancon, hopital Jean-Minjoz, pole cancerologie-oncologie medicale, 
      boulevard Fleming, 25000 Besancon cedex, France. Electronic address: 
      mariejustine.paillard@gmail.com.
FAU - Curtit, Elsa
AU  - Curtit E
AD  - CHU de Besancon, hopital Jean-Minjoz, pole cancerologie-oncologie medicale, 
      boulevard Fleming, 25000 Besancon cedex, France; Inserm U1098, 25000 Besancon, 
      France; Universite de Franche-Comte, SFR SMP, 25000 Besancon, France; EFS 
      Bourgogne Franche-Comte, UMR1098, 25000 Besancon, France.
FAU - Dobi, Erion
AU  - Dobi E
AD  - CHU de Besancon, hopital Jean-Minjoz, pole cancerologie-oncologie medicale, 
      boulevard Fleming, 25000 Besancon cedex, France.
FAU - Mansi, Laura
AU  - Mansi L
AD  - CHU de Besancon, hopital Jean-Minjoz, pole cancerologie-oncologie medicale, 
      boulevard Fleming, 25000 Besancon cedex, France.
FAU - Bazan, Fernando
AU  - Bazan F
AD  - CHU de Besancon, hopital Jean-Minjoz, pole cancerologie-oncologie medicale, 
      boulevard Fleming, 25000 Besancon cedex, France.
FAU - Villanueva, Cristian
AU  - Villanueva C
AD  - CHU de Besancon, hopital Jean-Minjoz, pole cancerologie-oncologie medicale, 
      boulevard Fleming, 25000 Besancon cedex, France.
FAU - Chaigneau, Loic
AU  - Chaigneau L
AD  - CHU de Besancon, hopital Jean-Minjoz, pole cancerologie-oncologie medicale, 
      boulevard Fleming, 25000 Besancon cedex, France.
FAU - Montcuquet, Philippe
AU  - Montcuquet P
AD  - CHU de Besancon, hopital Jean-Minjoz, pole cancerologie-oncologie medicale, 
      boulevard Fleming, 25000 Besancon cedex, France.
FAU - Meneveau, Nathalie
AU  - Meneveau N
AD  - CHU de Besancon, hopital Jean-Minjoz, pole cancerologie-oncologie medicale, 
      boulevard Fleming, 25000 Besancon cedex, France.
FAU - Thiery-Vuillemin, Antoine
AU  - Thiery-Vuillemin A
AD  - CHU de Besancon, hopital Jean-Minjoz, pole cancerologie-oncologie medicale, 
      boulevard Fleming, 25000 Besancon cedex, France; Inserm U1098, 25000 Besancon, 
      France; Universite de Franche-Comte, SFR SMP, 25000 Besancon, France; EFS 
      Bourgogne Franche-Comte, UMR1098, 25000 Besancon, France.
FAU - Nerich, Virginie
AU  - Nerich V
AD  - Inserm U1098, 25000 Besancon, France; Universite de Franche-Comte, SFR SMP, 25000 
      Besancon, France; CHU de Besancon, pole pharmacie, 25000 Besancon, France.
FAU - Pivot, Xavier
AU  - Pivot X
AD  - CHU de Besancon, hopital Jean-Minjoz, pole cancerologie-oncologie medicale, 
      boulevard Fleming, 25000 Besancon cedex, France; Inserm U1098, 25000 Besancon, 
      France; Universite de Franche-Comte, SFR SMP, 25000 Besancon, France; EFS 
      Bourgogne Franche-Comte, UMR1098, 25000 Besancon, France.
LA  - fre
PT  - Journal Article
TT  - Efficacite, tolerance et cout de l'eribuline chez des patientes presentant un 
      cancer du sein metastatique.
DEP - 20150526
PL  - France
TA  - Bull Cancer
JT  - Bulletin du cancer
JID - 0072416
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Furans)
RN  - 0 (Ketones)
RN  - LR24G6354G (eribulin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents/adverse effects/economics/*therapeutic use
MH  - Asthenia/chemically induced
MH  - Breast Neoplasms/*drug therapy/mortality/pathology
MH  - Female
MH  - Furans/adverse effects/economics/*therapeutic use
MH  - Humans
MH  - Ketones/adverse effects/economics/*therapeutic use
MH  - Middle Aged
MH  - Neutropenia/chemically induced
MH  - Peripheral Nervous System Diseases/chemically induced
MH  - Retrospective Studies
OTO - NOTNLM
OT  - Cancer du sein metastatique
OT  - Chemotherapy
OT  - Chimiotherapie
OT  - Cost
OT  - Cout
OT  - Eribulin
OT  - Metastatic breast cancer
OT  - Microtubule
OT  - Taxane
OT  - Eribuline
EDAT- 2015/05/30 06:00
MHDA- 2015/12/15 06:00
CRDT- 2015/05/30 06:00
PHST- 2014/08/31 00:00 [received]
PHST- 2015/03/25 00:00 [accepted]
PHST- 2015/05/30 06:00 [entrez]
PHST- 2015/05/30 06:00 [pubmed]
PHST- 2015/12/15 06:00 [medline]
AID - S0007-4551(15)00161-7 [pii]
AID - 10.1016/j.bulcan.2015.03.021 [doi]
PST - ppublish
SO  - Bull Cancer. 2015 Sep;102(9):737-48. doi: 10.1016/j.bulcan.2015.03.021. Epub 2015 
      May 26.